- Home
- SUZ vs GMAB Comparison
SUZ vs GMAB Comparison
Compare SUZ & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUZ
- GMAB
- Stock Information
- Founded
- SUZ 1924
- GMAB 1999
- Country
- SUZ Brazil
- GMAB Denmark
- Employees
- SUZ N/A
- GMAB N/A
- Industry
- SUZ Paper
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SUZ Basic Materials
- GMAB Health Care
- Exchange
- SUZ Nasdaq
- GMAB Nasdaq
- Market Cap
- SUZ 12.8B
- GMAB 15.0B
- IPO Year
- SUZ N/A
- GMAB N/A
- Fundamental
- Price
- SUZ $10.31
- GMAB $20.80
- Analyst Decision
- SUZ
- GMAB Buy
- Analyst Count
- SUZ 0
- GMAB 8
- Target Price
- SUZ N/A
- GMAB $43.00
- AVG Volume (30 Days)
- SUZ 1.6M
- GMAB 1.1M
- Earning Date
- SUZ 02-26-2025
- GMAB 02-12-2025
- Dividend Yield
- SUZ 2.32%
- GMAB N/A
- EPS Growth
- SUZ N/A
- GMAB 14.35
- EPS
- SUZ 0.60
- GMAB 10.80
- Revenue
- SUZ $8,006,653,403.00
- GMAB $2,967,926,227.00
- Revenue This Year
- SUZ $14.92
- GMAB $32.03
- Revenue Next Year
- SUZ $12.94
- GMAB $16.97
- P/E Ratio
- SUZ $16.65
- GMAB $18.81
- Revenue Growth
- SUZ N/A
- GMAB 17.75
- 52 Week Low
- SUZ $8.78
- GMAB $19.85
- 52 Week High
- SUZ $12.98
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- SUZ 54.09
- GMAB 45.42
- Support Level
- SUZ $9.93
- GMAB $19.89
- Resistance Level
- SUZ $10.30
- GMAB $21.26
- Average True Range (ATR)
- SUZ 0.19
- GMAB 0.40
- MACD
- SUZ 0.02
- GMAB -0.02
- Stochastic Oscillator
- SUZ 91.75
- GMAB 38.16
About SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.